CIM Securities analyst Kumaraguru Raja reiterated a Buy rating on Veru Inc (NASDAQ: VERU) on August 27 and set a price target of $10. The company’s shares closed yesterday at $1.95.
According to TipRanks.com, Raja is ranked #3775 out of 4872 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Veru Inc with a $8.33 average price target, representing a 327.2% upside. In a report issued on August 14, Maxim Group also maintained a Buy rating on the stock with a $10 price target.
.
See today’s analyst top recommended stocks >>
Based on Veru Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $7.93 million. In comparison, last year the company had a GAAP net loss of $789.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Veru, Inc. is a urology and oncology biopharmaceutical company, which engages in the development, manufacture, and marketing of consumer health care products. It operates through the Commercial; and Research and Development segments.
